Disease site committees discuss proposals for new studies, consider their scientific merit and feasibility, and assign priorities when necessary. Currently, there are 10 disease site committees including brain, breast, lung, gastrointestinal, genitourinary, gynecologic, hematologic, melanoma, sarcoma, and symptom control.
Each disease site committee is composed of representatives from centres participating in Canadian Cancer Trials Group trials whose primary function is to communicate to the Group the attitudes of their centres regarding trial proposals. Therefore, membership of disease site committees is centre-specific and is determined by the Centre Representative. Disease site committee representation is available to centres participating, or planning to participate, in Canadian Cancer Trials Group trials in the site in question. A Centre Representative may nominate up to three members to sit on a site committee to ensure relevant modalities are represented.